DGKA and melanoma: For example, DGKA is upregulated in melanoma, hepatocarcinoma and glioblastoma, where it contributes to the acquisition of tumor metastatic traits [21], and induces cisplatin and anti-PD-1 antibody resistance via crosstalk with kinase and transcription networks [22, 23].